

## GBM - Glioblastoma Multiforme

Subtype	Proliferation	Prognosis	Therapy (Typical / Investigational)	Common Driver Alterations
<b>Proneural</b>	Low– Moderate	Best (median OS ~17 months)	Surgery + radiation + temozolomide; IDH-mutant cases: IDH inhibitors; PDGFR inhibitors in trials	<b>PDGFRA</b> ampl/mut; <b>IDH1</b> mutation; <b>TP53</b> mutation; <b>ATRX</b> loss; <b>CIC</b> mutations
<b>Neural</b>	Moderate	Intermediate (median OS ~14 months)	Standard of care; no subtype-specific agents established; exploring neuronal-pathway targets	Expression of neuronal genes (e.g. NEFL, GABRA1); occasional <b>EGFR</b> ampl; <b>PTEN</b> loss
<b>Classical</b>	High	Intermediate (median OS ~14 months)	Standard of care; EGFR-targeted therapies have shown limited benefit; TERT inhibitors under study	<b>EGFR</b> ampl/mut (EGFRvIII); <b>CDKN2A</b> deletion chromosome 10 loss; <b>PTEN</b> mutation; <b>TERT</b> promoter mutation
<b>Mesenchymal</b>	High	Worst (median OS ~11 months)	Standard of care; trials of NF-κB pathway inhibitors, immunotherapies, MET inhibitors	<b>NF1</b> mutation/deletion; <b>PTEN</b> mutation; high <b>CHI3L1/CD44</b> expression; <b>TERT</b> promoter mutation